Sermorelin (30 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Sermorelin is a 29-amino-acid synthetic fragment that reproduces the biologically active region of human growth hormone–releasing hormone (GHRH 1–29). The figures below are compiled strictly for laboratory and educational reference — they describe how the compound has been handled and dosed in the published literature, not a recommendation for use in humans or animals.

For a 30 mg vial, adding 6.0 mL of bacteriostatic water yields a concentration of 5 mg/mL (5,000 mcg/mL). At that fill, each unit on a U-100 insulin syringe (0.01 mL) carries 50 mcg of material, so a 200 mcg increment lands cleanly on 4 units and the whole nightly range maps to round figures. This larger diluent volume is chosen deliberately because the active dose is in the low-microgram band, where a thin concentration keeps the syringe markings readable.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow nightly ramp used in the off-label adult literature, where the amount is stepped up roughly every two weeks while injection-site tolerability is assessed. Dosing is modelled as a single bedtime administration to coincide with the natural overnight GH pulse.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 6.0 mL of bacteriostatic water (two 3 mL or one 5 mL plus one 1 mL draw) and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until the solution is fully dissolved. Do not shake; vigorous agitation can shear the peptide.
4. The reconstituted solution should be clear and colourless. Label the vial with the concentration (5 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw each subsequent volume with a fresh sterile syringe.

Advanced (Steady-State) Schedule

Once the gradual ramp is complete, the published off-label model holds at the top of the studied band rather than escalating further, since Sermorelin works by amplifying the body's own pulsatile release and pushing higher offers diminishing return against the natural feedback ceiling. The schedule below reflects a maintenance plan held at 500 mcg nightly.

Supplies Needed

• Sermorelin vials (30 mg): 1 vial covers the full 8-week gradual ramp (~10 mg used); ~2 vials cover an 8-week ramp followed by ~10 weeks of 500 mcg maintenance.
• Insulin syringes (U-100, 0.3–0.5 mL, 28–31G): one fresh syringe per nightly draw — about 56 for an 8-week run, ~120 for a 16-week run.
• Bacteriostatic water (10 mL): one bottle reconstitutes one 30 mg vial (6 mL) with margin; a second bottle for a two-vial plan.
• Alcohol swabs: roughly two swabs per injection — a 100-count box covers about seven weeks; keep two boxes for longer runs.
• Sharps container: one puncture-proof container for spent syringes.

Protocol Overview

• Research goal: model endogenous, pulsatile GH secretion via GHRH-receptor stimulation rather than exogenous GH replacement.
• Schedule: once-nightly subcutaneous administration, timed to the natural sleep-onset GH pulse.
• Dose band: 200–500 mcg nightly in the adult off-label model; 30 mcg/kg nightly in pediatric GHD studies.
• Fill: 30 mg lyophilized, reconstituted to 5 mg/mL with 6 mL diluent.
• Storage: 2–8 °C sealed and after reconstitution; do not freeze.

Dosing Protocol Notes

• Begin at the 200 mcg step and hold each level for about two weeks before stepping up.
• Administer at bedtime to align with the overnight GH pulse used in the source model.
• Avoid eating immediately before a dose in the published protocols, as elevated blood glucose can blunt the GH response.
• Escalate only after injection-site tolerability is established at the prior step; the mid-band (300–400 mcg) carries most of the documented response signal.

Storage Instructions

Keep sealed lyophilized vials refrigerated at 2–8 °C (36–46 °F), protected from light and moisture, where stability extends for many months. Once reconstituted, keep the solution at 2–8 °C and use within about 10–14 days. Do not freeze reconstituted material, allow refrigerated solution to warm slightly before drawing, and avoid repeated temperature cycling.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Because the nightly volume is small (4–10 units), draw slowly and clear air bubbles to keep the measured dose accurate.
• Rotate sampling/handling technique to keep the rubber stopper intact across many draws.
• Document each draw — date, volume, remaining material — for reproducibility over a multi-week schedule.

How Sermorelin Works

Sermorelin is a truncated GHRH analog corresponding to the first 29 residues of native growth hormone–releasing hormone — the shortest fragment that retains full receptor activity. It binds GHRH receptors on the somatotrope cells of the anterior pituitary and prompts them to release the body's own stored growth hormone in a pulsatile pattern. Because the downstream output remains under normal negative feedback from somatostatin and circulating IGF-1, the system self-limits, which is the mechanistic basis for the lower supraphysiologic-GH risk reported against direct recombinant GH administration. Its short plasma half-life is why the published model places a single dose at night, mirroring the timing of natural GH secretion.

Reported Benefits & Side Effects

Benefits observed in studies

• Stimulation of endogenous, pulsatile GH release supporting physiologic IGF-1 levels.
• In pediatric growth-hormone-deficiency trials, meaningful improvements in height velocity over 6–12 months.
• In adults (off-label context), reported favorable shifts in body composition and metabolic markers.
• Preservation of the natural feedback loop, lowering the chance of supraphysiologic GH or IGF-1 excursions.

Side effects reported

• Injection-site reactions are the most common event (~17% incidence) — transient redness, pain or swelling.
• Rare systemic effects (under 1%) including headache, flushing, dizziness or hyperactivity.
• Subclinical hypothyroidism noted in roughly 6.5% of one cohort, prompting suggested thyroid monitoring.
• No serious acromegaly, hypoglycemia or excessive IGF-1 elevation at the recommended dose band.

Supporting Lifestyle Factors (Research Context)

• Adequate, consolidated sleep, since the largest endogenous GH pulse coincides with early slow-wave sleep targeted by nightly dosing.
• Avoidance of a high-glucose meal close to the dose, as hyperglycemia attenuates the GH response in the published designs.
• Resistance training and sufficient dietary protein as standard study-control conditions for body-composition endpoints.

Injection Technique (Reference Only)

• Choose a subcutaneous site — abdomen (at least two inches from the navel), outer thigh, upper arm or upper buttock — and swab a two-inch area, letting it dry.
• Draw air equal to the dose volume, inject it into the vial, invert, and withdraw the prescribed units.
• Pinch a skin fold and insert at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Depress the plunger slowly over a couple of seconds, pause before withdrawing, apply gentle pressure without rubbing, then rotate sites systematically and dispose of sharps in an approved container.

References

Related Protocols